Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tezepelumab

AstraZeneca AZ

AZ severe asthma drug benralizumab backed by CHMP

The IL-5 inhibitor set for European approval to treat severe eosinophilic asthma

Amgen appoints Wanda Austin to its Board

She will also serve as a member of the firm's audit committee

- PMLiVE

Asthma: beyond the blue and the brown

Innovation in respiratory medicine

AstraZeneca AZ

Setback for AZ as tralokinumab flunks asthma trial

Puts more pressure on AZ’s benralizumab to reach its potential

- PMLiVE

Amgen hopes its latest Kyprolis trial hits the mark with regulators

A.R.R.O.W study takes aim at once-weekly dosing regimen in multiple myeloma

Sanofi reception

US court lifts ban on sales of Sanofi’s Praluent

The duo can continue to compete against Amgen's rival PCSK9 Repatha

- PMLiVE

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

Stellar valuations for immuno-oncology candidates continue

- PMLiVE

AbbVie deal with Amgen sets biosimilar Humira launch dates

Agreement will see Europe access the drug over four years earlier than patients in the US

- PMLiVE

Amgen’s Mvasi is first FDA-approved cancer biosimilar

Offers prospect of lower-cost alternative to Roche's Avastin

- PMLiVE

GSK preps COPD filing for asthma pioneer Nucala

Moves despite reporting mixed data for the treatment earlier this year

- PMLiVE

Amgen signs real world study and mobile data partnership

Will work with health and wellbeing group Humana on risk prevention

- PMLiVE

Biocon backs away from biosimilar filings in Europe

EMA asks biotech to withdraw Herceptin and Neulasta biosimilar filings

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links